Overview

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Bristol-Myers Squibb
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc.
National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Mitogens